Literature DB >> 1895965

Comparison of reliability of plasma fructosamine and glycosylated hemoglobin assays for assessing glycemic control in diabetic patients on hemodialysis.

K Nunoi1, T Kodama, Y Sato, M Iwase, H Yoshizumi, H Kurimoto, H Nishitani, S Nakamura, M Fujishima.   

Abstract

To search for a reliable marker of medium-term integrated blood glucose level in diabetics on maintenance hemodialysis (HD), plasma fructosamine and glycosylated hemoglobin (Hb) levels were determined every week and blood glucose levels were determined four times every day over 3 weeks. The mean values of fructosamine (mol/L per 40 g of albumin) and of glycosylated Hb of other the study period correlated (r = .746, P less than .001) for combined materials of diabetic and nondiabetic subjects. However, plasma fructosamine values at the end of the study period did not correlate with the overall mean blood glucose values during the preceding 8 to 21 days (r = .372, NS). In contrast, glycosylated Hb values correlated closely with the same mean blood glucose values (r = .703, P less than .001). Fructosamine values significantly decreased during a HD, irrespective of the increases in albumin and total protein. In conclusion, glycosylated Hb was a reliable marker of long-term integrated blood glucose even in diabetics on HD. However, fructosamine was not a reliable marker of medium-term integrated blood glucose in these patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1895965     DOI: 10.1016/0026-0495(91)90077-a

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  6 in total

1.  The Effect of Glycated Hemoglobin and Albumin-Corrected Glycated Serum Protein on Mortality in Diabetic Patients Receiving Continuous Peritoneal Dialysis.

Authors:  Fenfen Peng; Xi Xia; Feng He; Zhijian Li; Fengxian Huang; Xueqing Yu
Journal:  Perit Dial Int       Date:  2014-11-13       Impact factor: 1.756

Review 2.  Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients.

Authors:  Dragana Lovre; Sulay Shah; Aanu Sihota; Vivian A Fonseca
Journal:  Endocrinol Metab Clin North Am       Date:  2017-12-18       Impact factor: 4.741

Review 3.  Glycemic control and burnt-out diabetes in ESRD.

Authors:  Csaba P Kovesdy; Jong C Park; Kamyar Kalantar-Zadeh
Journal:  Semin Dial       Date:  2010-03-30       Impact factor: 3.455

Review 4.  Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes.

Authors:  Elisa Danese; Martina Montagnana; Antonio Nouvenne; Giuseppe Lippi
Journal:  J Diabetes Sci Technol       Date:  2015-01-14

Review 5.  Glycated albumin is the preferred marker for assessing glycaemic control in advanced chronic kidney disease.

Authors:  Frederiek E Vos; John B Schollum; Robert J Walker
Journal:  NDT Plus       Date:  2011-12

6.  Increased body fat mass reduces the association between fructosamine and glycated hemoglobin in obese type 2 diabetes patients.

Authors:  Bruno Vergès; Alexia Rouland; Sabine Baillot-Rudoni; Marie-Claude Brindisi; Laurence Duvillard; Isabelle Simoneau; Pauline Legris; Jean-Michel Petit; Benjamin Bouillet
Journal:  J Diabetes Investig       Date:  2020-09-17       Impact factor: 4.232

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.